| The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis C Khanna, X Wan, S Bose, R Cassaday, O Olomu, A Mendoza, C Yeung, ... Nature medicine 10 (2), 182-186, 2004 | 983 | 2004 |
| Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 520 | 2014 |
| KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study BD Shah, A Ghobadi, OO Oluwole, AC Logan, N Boissel, RD Cassaday, ... The Lancet 398 (10299), 491-502, 2021 | 424 | 2021 |
| Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy KA Hay, J Gauthier, AV Hirayama, JM Voutsinas, Q Wu, D Li, TA Gooley, ... Blood, The Journal of the American Society of Hematology 133 (15), 1652-1663, 2019 | 339 | 2019 |
| The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, T Gooley, D Li, ... Blood, The Journal of the American Society of Hematology 133 (17), 1876-1887, 2019 | 283 | 2019 |
| Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised … HM Kantarjian, DJ DeAngelo, AS Advani, M Stelljes, P Kebriaei, ... The Lancet Haematology 4 (8), e387-e398, 2017 | 168 | 2017 |
| Outcomes of patients with double-hit lymphoma who achieve first complete remission DJ Landsburg, MK Falkiewicz, J Maly, KA Blum, C Howlett, T Feldman, ... Journal of Clinical Oncology 35 (20), 2260, 2017 | 165 | 2017 |
| Acute lymphoblastic leukemia, version 2.2015 JC Alvarnas, PA Brown, P Aoun, KK Ballen, SK Barta, U Borate, ... Journal of The national comprehensive cancer network 13 (10), 1240-1279, 2015 | 136 | 2015 |
| Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies J Gauthier, ED Bezerra, AV Hirayama, S Fiorenza, A Sheih, CK Chou, ... Blood, The Journal of the American Society of Hematology 137 (3), 323-335, 2021 | 120 | 2021 |
| KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results BD Shah, MR Bishop, OO Oluwole, AC Logan, MR Baer, WB Donnellan, ... Blood, The Journal of the American Society of Hematology 138 (1), 11-22, 2021 | 115 | 2021 |
| Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy VA Chow, AK Gopal, DG Maloney, CJ Turtle, SD Smith, CS Ujjani, ... American journal of hematology 94 (8), E209, 2019 | 114 | 2019 |
| Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy SD Smith, BG Till, MS Shadman, RC Lynch, AJ Cowan, QV Wu, ... British journal of haematology 189 (6), 1119-1126, 2020 | 93 | 2020 |
| Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and … Z DeFilipp, AS Advani, V Bachanova, RD Cassaday, DJ Deangelo, ... Biology of Blood and Marrow Transplantation 25 (11), 2113-2123, 2019 | 92 | 2019 |
| Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma DJ Landsburg, AM Petrich, JS Abramson, AR Sohani, O Press, ... Cancer 122 (4), 559-564, 2016 | 91 | 2016 |
| A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients RD Cassaday, PM Sondel, DM King, MD Macklin, J Gan, TF Warner, ... Clinical cancer research 13 (2), 540-549, 2007 | 91 | 2007 |
| Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy M Shadman, J Gauthier, KA Hay, JM Voutsinas, F Milano, A Li, ... Blood advances 3 (20), 3062-3069, 2019 | 88 | 2019 |
| NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017 PA Brown, B Shah, A Fathi, M Wieduwilt, A Advani, P Aoun, SK Barta, ... Journal of the National Comprehensive Cancer Network 15 (9), 1091-1102, 2017 | 75 | 2017 |
| A Randomized Controlled Trial of Octreotide Pamoate Long-acting Release and Carboplatin versus Carboplatin Alone in Dogs with Naturally Occurring … C Khanna, J Prehn, D Hayden, RD Cassaday, J Caylor, S Jacob, ... Clinical Cancer Research 8 (7), 2406-2412, 2002 | 73 | 2002 |
| Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma … DJ Landsburg, MK Falkiewicz, AM Petrich, BA Chu, A Behdad, S Li, ... British journal of haematology 175 (4), 631-640, 2016 | 71 | 2016 |
| Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies G Falchook, S Rosen, P LoRusso, J Watts, S Gupta, CC Coombs, ... Clinical Cancer Research 26 (6), 1247-1257, 2020 | 68 | 2020 |
